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20S-protopanaxadiol (aPPD) is a metabolite of ginseng saponins, which is reported to be pro-apoptotic in some cells but anti-
apoptotic in neuronal cells by regulating Akt signaling. Owing to its cholesterol-like structure, we hypothesized that aPPD may
regulateAktsignalingbyinteractingwithlipidrafts.Here,wecomparedAktsignalinginglioblastomaU87MGandneuroblastoma
Neuro-2a cells treated with aPPD. aPPD did not change Akt activity in the total plasma membranes of each cell type, but
drastically altered the activity of raft-associated Akt. Strikingly, Akt activity was decreased in the rafts of U87MG cells but
increased in N2a cells by aPPD through regulating raft-associated dephosphorylation. The bidirectional regulation of raft-
associated Akt signaling by aPPD enhanced the chemotoxicity of Paclitaxel or Vinblastine in U87MG cells but attenuated the
excitotoxicity of N-methyl-D-aspartate in N2a cells. Our results demonstrated that the activity of raft-associated but not total
membrane Akt determines its cellular functions. Lipid rafts differ in different types of cells, which allows for the possibility of
cell-type-speciﬁc targeting for which aPPD might prove to be a useful agent.
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20S-protopanaxadiol (aPPD) is a gastrointestinal metabolite
of ginseng saponins. The latter are the main pharmacologi-
cally active components in ginseng. aPPD is an interesting
compound that seems to have opposite effects on non-
neuronal cells and neuronal cells. Previous studies by our
group and others have shown that aPPD inhibited Akt activity
and induced apoptosis in various tumor cells.
1–3 However,
aPPD has also been demonstrated to protect neuronal cells
against glutamate and N-methyl-D-aspartate (NMDA)-in-
duced excitotoxicity
4,5 and to stimulate neuronal cell regen-
eration by activating the Akt pathway.
6,7 The mechanism
underlying the cell-type-dependent effects of aPPD has not
yet been elucidated.
The plasma membrane (PM), as a major site of Akt
activation,containsmultiplemicrodomains,andamongthese,
a cholesterol-rich, detergent-resistant type of microdomain
known as the lipid raft has been suggested as a critical
platform for cell signaling.
8,9 Lipid rafts function as contribu-
tors to lateral membrane heterogeneity and are generated
through lipid–lipid and speciﬁc lipid–protein interactions.
10
Owing to the long and saturated fatty acids of sphingolipids
and cholesterol, lipid rafts exist in the liquid-ordered phase. In
contrast, other PM compartments occur in the liquid-dis-
ordered phase because they are composed of phospholipids
with short and unsaturated fatty acids.
11 Cholesterol is
believed to serve as a spacer between the hydrocarbon
chainsofsphiongolipidsandtofunctionasadynamicgluethat
keeps the raft assembly together.
12
Akt signaling in PM microdomains has only recently been
examined as an important oncogenic pathway.
13–15 The
binding of growth factors to their receptor tyrosine kinases
stimulates the phosphorylation of phosphatidylinositol
3-kinase (PI3K) comprised of P85 and P110 subunits, which
localize to lipid rafts. PI3K converts phosphatidylinositol-4,5-
bisphosphate (PI(4,5)P2) to phosphotidylinositol-3,4,5-tri-
sphosphate (PI(3,4,5)P3), whereas phosphatase and tensin
homolog deleted on chromosome 10 reverses this reaction.
Akt translocates to the PM and interacts with PI (3,4,5)P3 via
its PH domain and is, respectively, phosphorylated at two
residues (Thr308 and Ser473) by phosphoinositide-depen-
dent kinase (PDK) and various raft-associated kinases,
including mTORC2 and integrin-linked kinase (ILK).
16,17
OneoftheﬁrsttargetsofAktshowntohavedirectimplications
in the regulation of cell survival is a member of the
proapoptotic Bcl-2-family and is known as Bcl-2-associated
death (BAD). It is attached to lipid rafts in proliferating cells,
although associated to mitochondria in apoptotic cells.
12,18
Once phosphorylated, the phosphoserine residues (Ser136
and Ser112) of BAD form afﬁnity-binding sites for 14-3-3
molecules, thus localizing phosphorylated BAD to the cytosol
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19,20
Recent studies indicated that raft-associated Akt could be
an important determinant of oncogenicity.
21,22 Studies of
small-cell lung cancer cells showed that speciﬁc PI3K
isoforms reside in lipid rafts and that disruption of membrane
rafts by methyl-b-cyclodextrin (MbCD) inhibits PI3K-mediated
Akt activity.
23 Live-cell ﬂuorescence imaging has shown that
raft Akt is activated faster and more potently than non-raft Akt,
presumably because of compartmentalization of various
componentsofthesignaling pathway,includingthe receptors,
PI3K and Akt itself.
22
Given their saponin-like structure, ginsenosides are well
known for their ability to increase the ﬂuidity of cellular
membranes.
11,24 As the structure of aPPD highly resembles
that of cholesterol, we hypothesized that this compound may
interfere with lipid rafts and alter lateral movement of raft
resident proteins. We further speculated thatdifferent types of
cells might differ in the resident proteins of their lipid rafts,
which may explain the abovementioned contrast in the effects
of aPPD on neurons versus non-neuronal cells. To test the
above hypothesis, we used the glioma cell line U87MG and
the neuroblastoma cell N2a for our investigation. Although
both the cells have a nerve tissue origin, they differ in that
U87MG is derived from glial cells and N2a is a neuronal cell
type.
25,26FollowingtreatmentofbothcelltypeswithaPPD,we
investigated the Akt signaling pathway in the lipid rafts and
consequently, their cellular response to chemotherapeutic
and excitotoxic agents. Our results showed that aPPD altered
raft-associated Akt activity differently in the two cell lines but
not in the total PM. Moreover, the cellular outcomes to a toxic
stimulus were opposite, indicating that the pharmacological
effects of this compound can be completely cell-type-speciﬁc
because of differences in its effect on the raft-associated cell
signaling of different cells.
Results
aPPD affects lipid rafts differently from MbCD and these
effects are cell-type dependent. To demonstrate the
differential effects of aPPD on lipid rafts in the two cell
lines, we looked at changes in cholesterol concentrations of
various PM fractions of U87MG and N2a cells treated with
aPPD or MbCD. The latter is a well-known lipid raft disruptor,
which functions by depleting membrane cholesterol.
11,27 To
examine whether aPPD is cytotoxic to the cells, cell mortality
were measured with different concentrations of aPPD at
different time points. Although treatment with 10mM aPPD
had no effect on cell mortality at 4h for both cells
5.20±2.45%, P¼0.196) for U87MG and 3.76±5.97%,
P¼0.276) for N2a cells), the mortality increased slightly,
but not statistically signiﬁcant by 24h (12.64±13.57%,
P¼0.089 in U87MG cells and 11.30±10.41% in N2a cells,
P¼0.059). Signiﬁcant cell death was observed at 24h in
cells treated with 20mM aPPD, especially not only for U87MG
(42.7±14.78%, P¼0.002) but also for N2a to a less degree
(23.12±5.39, P¼0.002). Thus, 10mM aPPD was used in the
following experiments. Cellular membranes were separated
at 4h after treating with 10mM aPPD through
ultracentrifugation into 12 fractions (Figure 1b). The lipid
rafts were mainly located in fraction 5 as demonstrated by
western blots of ﬂotillin-1, a lipid raft marker (Figure 1c). As
expected, the maximum cholesterol content was also found
in fraction 5 of both untreated U87MG and N2a cells (Figures
2a and b), further conﬁrming enrichment of the lipid rafts in
this fraction. Treatment with 10mM MbCD completely
diminished the cloudy appearance of fraction 5 of
membrane proteins of both cell types (Figure 2c) and
signiﬁcantly reduced the levels of total cholesterol in this
fraction (Figures 2a and b), suggesting a complete disruption
of the lipid rafts of both cell types by this agent. Treating cells
of both lines with aPPD also diminished the cloudy
appearance of fraction 5 (Figure 2d). Surprisingly, however,
there was no change in cholesterol levels in this fraction
(Figures 2a and b), indicating that, unlike MbCD, aPPD does
not cause any depletion of membrane cholesterol.
Furthermore, levels of ﬂotillin-1 protein in both U87MG and
N2a cells decreased in fraction 5 after MbCD treatment
(Figure 3a). However, treatment with aPPD reduced the
ﬂotillin-1 concentration in U87MG cells only. Instead, aPPD
treatment upregulated the ﬂotillin-1 level in the rafts of N2a
cells to 142.91±10.71% of the control, as shown in
Figure 3b. Taken together, these data suggested that
aPPD can interfere with lipid rafts but not by the same
mechanism used in the case of MbCD. Furthermore, aPPD
can have an opposite effect on raft resident protein ﬂotillin-1,
depending on the cell type.
aPPD alters raft-associated Akt phosphorylation without
changing the total membrane Akt level. We then asked
whether aPPD altered levels of Akt and its phosphorylation
status in the cellular membrane of the two types of cells.
Western blots of total Akt and its two phosphorylation
residues, Thr308 and Ser473, were performed with total
membrane proteins of U87MG and N2a cells treated with
aPPD. Figures 4a and b show that there were no signiﬁcant
changes in Akt or its state of phosphorylation in the PM of
each type of aPPD-treated cells.
Interestingly, Akt and its phosphorylation state were totally
differentinthelipidraftsisolatedfromthetwodifferenttypesof
aPPD-treated cells. As shown in Figures 4c and d, although
aPPD did not signiﬁcantly change the total level of Akt in the
lipid rafts of the two cell types, phosphorylation at Thr308 and
Ser473 was signiﬁcantly reduced in U87MG cells but
increased in N2a, indicating that aPPD may inhibit raft-
associated Akt activity in U87MG cells but stimulate this
activity in N2a cell.
aPPD regulates Akt activity in lipid rafts by altering
levels of raft-associated phosphatases. To determine
how aPPD selectively activates raft-associated Akt activity
in N2a cells but inhibits it in U87MG cells, we measured
levels of PI3K, PDK and ILK in the lipid rafts, which are
known as upstream kinases that regulate the
phosphorylation of Akt.
17 As shown in Figure 5a, we noted
no signiﬁcant changes in PI3K, including activity involving the
regulatory subunit P85 and the catalytic subunit P110a, after
aPPD treatment of either U87MG or N2a cells. We further
investigated whether raft levels of PDK1 and ILK, which,
respectively, phosphorylate Thr308 and Ser473 of Akt, were
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Cell Death and Diseaseaffected by the aPPD treatment. Figure 5b shows that the
amount of PDK1 did not change signiﬁcantly in each type of
aPPD-treated cell. However, the amount of ILK1 in the lipid
rafts of N2a cells increased signiﬁcantly, whereas it
decreased in those of U87MG. Finally, we measured levels
of two major phosphatases, PH domain leucine-rich repeat
phosphatase 1 and 2 (PHLPP1 and 2), that are responsible
for Akt dephosphorylation.
28–33 Our results (Figure 5c)
showed that treatment with aPPD caused signiﬁcant
changes in both PHLPP1 and PHLPP2 in lipid rafts.
Strikingly, the level of PHLPP1 and PHLPP2 in the rafts
increased by 56.31±5.12 and 82.97±5.02%, respectively,
in U87MG cells but decreased by 30.38±3.94 and
30.22±8.31% in N2a cells.
Bidirectional regulation of Akt functions of glioma
cells versus neuronal cells. To examine whether the
contrasting effects of aPPD on raft-associated Akt in the
two types of cells correlate with a difference in their
respective pharmacological responses, we measured cell
viability under toxic insult with or without aPPD. U87MG cells
were treated with different concentrations of Paclitaxel
(TAXOL) (Bristol-Myers Squibb, Toronto, ON, Canada), or
Vinblastine and N2a cells were treated with NMDA. Both
cells were co-treated with 10mM aPPD. Remarkably
enhanced toxicity was evident in U87MG cells co-treated
with aPPD and TAXOL or Vinblastine (Figures 6a and b). In
contrast, aPPD strongly protected N2a cells from NMDA-
induced excitotoxicity (Figure 6c).
Figure1 Isolationandidentiﬁcationoflipidrafts.(a)Thechemicalstructureof20S-Protopanaxadiol(aPPD).(b)Membranepreparationsaftercentrifugationtoisolatelipid
rafts as described in Materials and methods. Lipid rafts were mainly in fraction 5 appearing as an opaque band. (c) Proteins in each fraction shown in (b) were analyzed by
SDS-PAGEandblottedwithﬂotillin-1antibody.Asalipidraftresidentprotein,ﬂotillin-1wasmainlypresentinfraction5(sometimesalsoin6).Allresultsarerepresentativeofat
least three independent experiments
Figure 2 aPPD does not deplete cholesterol in the membrane. (a) The cholesterol concentrations in the PM and each fraction of U87MG cells measured with an Amplex
Red cholesterol assay kit. (b) The cholesterol concentrations in the PM and each fraction of N2a cells. The highest level of cholesterol was detected in fraction 5 in both cell
lines. (c and d) Cellular membrane samples of 10mM MbCD- or 10mM aPPD-treated U87MG and N2a cells collected by centrifugation. Although both MbCD and aPPD
caused a disappearance of the opaque band, only MbCD and not aPPD depleted cholesterol (a and b). *Po0.05, **Po0.001 compared with the control, t-test (n¼3
independent experiments)
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Cell Death and DiseaseFinally, we asked whether the above difference in the
pharmacological effects of aPPD could be attributed to its
different effects on the Akt pathway in the lipid rafts of the two
cell lines under the toxic insults. We compared levels of raft-
associated Akt and phosphorylated Akt, as well as BAD. The
latter is a downstream target of Akt, and BAD phosphorylation
is an important anti-apoptotic mechanism of Akt signaling.
Neither TAXOL nor Vinblastine signiﬁcantly altered Akt
activity in the lipid rafts of U87MG cells (Figures 7a and c).
In addition, both chemotherapeutic agents signiﬁcantly
reduced the total levels of BAD in the lipid rafts of U87MG
cells but did not affect their phosphorylation state (Figures 7b
and d). On the other hand, NMDA signiﬁcantly reduced
phosphorylation of Akt in the lipid rafts of N2a cells and
consequently, the phosphorylation of raft-associated BAD
was also reduced (Figures 7e and f). As expected, aPPD
drastically suppressed Akt phosphorylation in the lipid rafts in
TAXOL- or Vinblastine-treated U87MG cells. Levels of BAD
phosphorylation were also signiﬁcantly reduced (Figures 7a-d).
In contrast, aPPD restored the phosphorylation status of Akt
and BAD in the lipid rafts of NMDA-treated N2a cells (Figures
7e and f). Thus, these results conﬁrm that aPPD exerts
opposite pharmacological effects on these different cell types
and this cell-type-speciﬁc, bidirectional phenomenon can be
attributed to the cell-type-speciﬁc difference in the activity of
aPPD in raft-associated Akt signaling.
Figure 3 Levels of ﬂotillin-1 in the lipid rafts of both U87MG and N2a cells treated with either MbCD (a) or aPPD (b). *Po0.05, **Po0.001 compared with the control, t-
test (n¼3 independent experiments)
Figure 4 Effect of aPPD on Akt activity in the cellular membrane. aPPD had no effect on the Akt concentration or its phosphorylation state in either U87MG or N2a cells
(a and b). aPPD regulates Akt phosphorylation in the lipid rafts of U87MG and N2a cells in an opposite manner (c and d). *Po0.05 compared with the control, t-test (n¼3
independent experiments)
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Cell Death and DiseaseaPPD inhibits glioma cell migration. Raft-associated Akt
signaling pathway is known to regulate cell invasion and
motility.
34 Thus, in vitro scratch assay
35 was performed to
measure 24-h cell migration rates of both U87MG and N2a
cells treated with aPPD. Figure 8 showed that treatment with
aPPD signiﬁcantly inhibited cell migration in U87MG cells
(53.2±20.1% of control, P¼0.0002), but had much less
effect on N2a cells (82.4±20.8%, P¼0.166).
Discussion
The above results clearly show that (1) aPPD is highly
effective in interfering with the protein composition of the lipid
rafts without altering the level of cholesterol; (2) the effects of
aPPD on the raft resident proteins are highly cell-type
dependent; (3) aPPD suppresses the activity of the Akt
pathway in the lipid rafts of glioma cells but increases it in
neuronal cells without affecting the Akt activity in the total PM
of both types of cells; (4) the raft-associated Akt activity is
regulated by aPPD by altering the levels of phosphatases in
the raft; (5) the difference in the effect of aPPD on the activity
of the raft-associated Akt pathway results in inhibition on cell
migration and enhanced cytotoxicity with TAXOL or Vinblas-
tine in U87MG cells, but attenuated excitotoxity with NMDA in
N2a cells; Our study demonstrates that the ﬁnal metabolite of
protopanaxadiol ginsenosides, aPPD, is a highly effective raft
disruptor. Unlike MbCD, aPPD alters the contents of resident
proteins in the lipid rafts without changing the levels of
cholesterol. Rh2, a glycosylated form of protopanaxadiol has
also been shown to inﬂuence the lateral movement of Fas
between raft and non-raft microdomains of the cellular
membrane.
11 As aPPD is structurally more similar to
cholesterol, it would not be surprising if it functions as a
stronger raft disruptor through intercalating itself into the lipid
Figure 5 Effects of aPPD on Akt regulators in lipid rafts. (a) There were no signiﬁcant changes in levels of P85 and P110a of PI3K after treatment with aPPD in either
U87MGcellsorN2acells.(b)TheamountofPDK1didnotchangesigniﬁcantlyinaPPD-treatedcellsofeachcellline.However,theamountofILK1inthelipidraftssigniﬁcantly
increasedinN2acellsanddecreasedinU87MGcells.(c)ThelevelsofPHLPP1andPHLPP2intheraftssigniﬁcantlyincreasedinU87MGcellsbut,respectively,decreasedin
N2a cells. *Po0.05 compared with the control, t-test (n¼4 independent experiments)
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Cell Death and Diseaserafts to cause changes in the microenvironment of the
membrane, which in turn results in an alteration of the protein
composition of the lipid rafts. It remains to be determined
whether aPPD alters raft resident proteins by causing a
general alteration in the ﬂuidity of the membrane, similar to
other cholesterol derivatives,
36 or whether the compound
directly interacts with speciﬁc proteins in the lipid rafts to
modulate their activity. It is worth noting that even though
aPPD does not change the cholesterol level in the lipid rafts, it
caused the opacity of the lipid raft fraction to disappear, as did
MbCD (Figure 2). As the opacity might indicate the presence
ofaspeciﬁcformofcomplex containinginsoluble proteinsand
lipid, its aPPD-induced disappearance clearly suggests that
thecompoundcanalterthephysicalstateoftheproteinsinthe
lipid rafts.
The most striking ﬁnding of the present investigation is that
aPPD regulates the raft-associated Akt pathway of glioma
cells and neuronal cells in an opposite manner. aPPD
downregulates Akt phosphorylation in U87MG cells but
upregulates the phosphorylation in N2a cells. Results showed
that this bidirectional regulation of the activity of raft-
associated Akt by aPPD was not due to changes in the
activity of PI3K or PDK1 in the rafts (Figure 5). The latter is
responsible for phosphorylation at Thr308, which is thought to
be essential for Akt activation.
37 As aPPD altered the Akt
phosphorylation status with no change in PI3K or PDK1, it is
more likely that Akt activity was regulated by changes in raft-
associated phosphatases. Indeed, cell-type-speciﬁc altera-
tioninraft-associatedPHLPPswasobservedinaPPD-treated
cells. Both phosphatases are known for their role in attenuat-
ing the total level of Akt hydrophobic motif phosphorylation
and cell survival.
28 There is no obvious explanation for the
contrasting effects of aPPD on the two cell lines with respect
to Akt signaling in their lipid rafts. It has been reported that
PHLPP1 might be associated with Akt2 and Akt3, whereas
PHLPP2 might be with Akt1 and Akt3.
33 It remains to be
studied whether differential distribution of the Akt isoforms
and their PHLPPs has any role in their functions in the lipid
rafts of different cell types. Alternatively, it is also possible that
cells may differ in the respective structures of lipid rafts such
as those reﬂecting the composition of resident proteins, and
that these differences could be elucidated with lipid raft
proteomic analysis.
38
The above bidirectional regulation of raft-associated Akt
signaling by aPPD is highly consistent with the contrasting
pharmacological activity of this compound in U87MG cells
andN2acellswhenco-stimulatedwithtoxicinsult(Figure6).It
is interesting that, in U87MG cells, both TAXOL and
Vinblastine signiﬁcantly reduced the total amount of raft-
associated BAD, the phosphorylating target of Akt, without
changing the amount of phosphorylated BAD in the lipid
rafts. As there was no signiﬁcant difference in Akt activity in
the rafts of drug-treated cells, it appears that the chemother-
apeutic agents increased the ratio of phosphorylated
BAD to non-phosphorylated BAD in the lipid rafts by removal
of the latter from these structures. Interestingly, in N2a
cells, NMDA inhibited phosphorylation of raft-associated Akt
and BAD without changing the total amounts of these proteins
in the lipid rafts. Finally, aPPD enhanced chemotoxicity in
U87MG cells and protected N2a cells from NMDA-induced
excitotoxicity. These bidirectional effects were in agreement
with the changes observed in Akt activity as well as
in its downstream target BAD in the lipid rafts of the two cell
types, which may directly correlate with the cell-type-
dependent pro-apoptotic or anti-apoptotic effect of aPPD.
More importantly, the fact that aPPD’s pharmacological
functions correlate with activity of raft-associated Akt
but not that in the total PM further emphasizes the notion
that only raft-associated Akt determines the functions of its
signaling.
Figure 6 aPPD enhanced the cytotoxic effect of chemotherapeutic agents in
glioma cells and attenuated the cytotoxic effect in NMDA-treated neuronal cells.
(a and b) U87MG cells were incubated with or without 10mM aPPD in the presence
of different concentrations of either Paclitaxol (TAXOL) or Vinblastine. (c) aPPD
remarkably reduced NMDA-induced neuroexcitotoxicity in N2a cells. *Po0.05,
**Po0.001 compared with the control, t-test (n¼3 independent experiments)
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Cell Death and DiseaseIn the present study, we show that only phosphorylation of
raft-associated Akt determines the activity and direction of Akt
signaling,asaPPDhasnoeffectonAktphosphorylationinthe
total PM of the two cell types. This underlines the importance
of focusing on membrane microdomains instead of the global
cellular membrane when the functions of signaling proteins
are studied. Our results are the ﬁrst to clearly demonstrate
that cells can be differentially targeted according to
differences in the structures of their membrane microdo-
mains, and aPPD was used here as the ﬁrst agent to be
applied for this purpose.
Materials and Methods
Materials. aPPD was provided by Shanghai Innovative Research Centre of
Traditional Chinese Medicine (Shanghai, China). The compound was 97.9% pure
as measured by HPLC analysis. Antibodies to phosphor-Akt (Ser
473), phosphor-Akt
Figure 7 Akt signaling in lipid rafts of U87MG and N2a cells treated with chemotherapeutics and NMDA with and without aPPD. Total Akt and Akt phosphorylation in the
lipid rafts were inhibited by aPPD in U87MG cells treated with TAXOL or Vinblastine (a and c). Phosphorylation of BAD in the lipid rafts was also reduced by aPPD (b and d).
aPPD restored phosphorylation of Akt and BAD in the lipid rafts of N2a cells treated with NMDA (e and f). *Po0.05, **Po0.001 compared with the control, t-test (n¼3
independent experiments)
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Cell Death and Disease(Thr
308), Akt (pan), PI3 Kinase p85, PI3 Kinase p110a, ILK1, phosphor-PDK1
(Ser
241),BAD,phosphor-BAD(Ser
112)andphosphor-BAD(Ser
136)werepurchased
from Cell Signalling Technology, Inc. (Mississauga, Ontario, Canada). Flotillin-1
antibody was purchased from Abcam, Inc. (Cambridge, MA, USA). PHLPP1 and
PHLPP2 antibodies were purchased from Bethyl Laboratories, Inc. (Montgomery,
TX, USA). HRP-conjugated anti-rabbit and anti-mouse IgG were purchased from
Perkin-Elmer Life Sciences (Boston, MA, USA). Protease inhibitor cocktails were
obtained from Roche Molecular Biochemicals (Mannheim, Germany). A modiﬁed
DC protein assay kit and nitrocellulose membranes were purchased from BIO-RAD
(Hercules, CA). MbCD, Vinblastine, NMDA, media (Dulbecco’s modiﬁed Eagle’s
medium, DMEM), thiazolyl blue tetrazolium bromide (MTT) and other chemicals
were purchased from Sigma (St. Louis, MO, USA). Paclitaxel was purchased from
the pharmacy of the British Columbia Cancer Agency (Vancouver, BC, Canada).
U87MG cells and N2a cells were purchased from American Type Culture Collection
(ATCC) (Manassas, VA, USA). Phosphate-buffered saline (PBS), cell culture
supplements (fetal bovine serum (FBS) and antibiotics were obtained from GIBCO
BRL (Gaithersburg, MD, USA).
Cell cultures and treatments. Human U87MG and N2a cells were cultured
in DMEM supplemented with 10% FBS, 100U/ml penicillin and 100mg/ml
streptomycin, at371Cin a humidiﬁedatmospherecontaining5% CO2 andfedevery
2–3 days. A stock solution of 50mM aPPD was prepared in 100% ethanol and
diluted to proper concentrations in DMEM immediately before each experiment.
Drug-treatment cells were pretreated with DMEM for 4h at 371C, followed by the
addition of 10mM MbCD or 10mM aPPD for 1h.
Lipid raft isolation. Cells in ﬁve 100-mm dishes were mixed with 3ml of lysis
buffer per dish (150mM NaCl, 20mM Na2HPO4, 2mM NaH2PO4, 20% (v/v)
glycerol, 2mM sodium orthovanadate with protease inhibitors, pH 7.4) and
homogenized 30 times with a tight Dounce homogenizer (Sigma). Samples were
further disrupted by intermittent sonication (six 30-s pulses with a 1min cooling
period between) and then centrifuged at 10K r.p.m. (Beckman-Coulter Optima L-
90K ultracentrifuge with an SW55Ti rotor, Mississauga, ON, Canada) for 11min at
41C to separate cell debris and nuclear materials. The supernatant was then
centrifuged at 32.5K r.p.m. (SW55Ti rotor) for 90min at 41C to pellet the PM. The
PM was suspended and solubilized in 2ml solubilizing buffer containing 0.5% v/v
Triton X-100 in Mes-buffered saline (MBS: 25mM Mes, pH 6.5/0.15M NaCl),
proteaseinhibitors and 2mMsodium orthovanadate for 15min on ice. Then, 2ml of
solubilized PM were further diluted with an equal volume of 80% sucrose in MBS
and loaded on the bottom of a 13ml ultracentrifuge tube overlaid with 4ml of 30%
sucrose/MBS. Finally, 4ml of a 5% sucrose/MBS solution were added as the top
layer of the gradient. The gradient was centrifugated at 31K r.p.m. (SW41Ti rotor)
for 16h at 41C to isolate the lipid raft and non-raft compartments. The gradient was
then fractionated into 12 fractions.
39
Western blotting. The protein concentration was measured using a modiﬁed
DC protein assay. An equal volume of fraction (10ml/lane) from each sample was
separated on a polyacrylamide gel. For immunoblotting, the proteins were
transferred onto nitrocellulose membranes using a wet transfer system (BIO-RAD).
The membranes were blocked with 5% non-fat milk (BIO-RAD) for 1h at room
temperature and probed with primary antibodies at 41C overnight. The membranes
were then washed three times with Tris-buffered saline with 0.05% Tween 20
(TBST)and incubated with HRP-conjugated anti-rabbitor goat IgG (1:5000) for 1h
at room temperature. Signals were detected using enhanced chemiluminescence
(Perkin-Elmer Life Sciences) and band intensities were quantiﬁed using Image
J software (NIH, Bethesda, MD, USA).
Cholesterol measurement. Fifty microliters of each fraction were analyzed
with an Amplex Red cholesterol assay kit (Molecular Probes, Eugene, OR, USA)
according to the manufacturer’s protocol.
MTT assay. For cell viability, cells were seeded in 96-well plates at a density of
2.5 10
4/well,1daybeforeexperiments.CultureswerethenincubatedwithDMEM
containing TAXOL, Vinblastine or NMDA, with or without aPPD (10mM) for 24h at
371C. At the end of each time point, the culture medium was removed and 50mlo f
MTT (0.5mg/ml in serum-free medium) were added to each well. Following
incubation at 371C for 4h, 100ml of lysis buffer (50v/v N,N-dimethylformamide
(Sigma), 20% SDS (BIO-RAD) and 0.4% (v/v) glacial acetic acid in distilled water
(pH 4.8)) were added and the plates were incubated overnight in a humidiﬁed
atmosphere (371C with 5% CO2). The optical density of each well was determined
with a microplate reader (BIO-TEK, Winooski, VT, USA) at 595nm.
Figure 8 EffectsofaPPDoncellmigrationofU87MGandN2acells.(a)Migrationofcellsinculturedishes.Theedges(dottedlines)ofculturedU87MGcellsat0and24h
after scratch were shown as the injury line and the migration line, respectively. The migration area was calculated as regions between the injury and migration lines.
(b) Quantiﬁcationof the cell migrationrate. The migrationrate of U87MG cells was effectively reducedwith the treatment of aPPD in U87MGbut not N2a cells. The data were
the averages of two repeated experiments with quadruplets for each time, *Po0.05 compared to the control
Akt signaling pathway and lipid rafts
Y Liu et al
8
Cell Death and DiseaseCell migration assay. U87MG or N2a cells were cultured in six-well culture
dishes to 70–90% conﬂuence, followed by scratch with 1ml sterilized pipette tips.
After washing with pre-warmed PBS, cells were cultured in serum-free DMEM for
24h. Images were taken at 0 and 24h after scratch by Zeiss Axiovert 200
microscope (Zeiss, Toronto, ON, Canada) with  5 (for U87MG cells) or  10 (for
N2a cells) objectives. Images of same spots taken at 0 and 24h were overlaid and
adjusted with Photoshop CS4 software (Adobe, Ottawa, ON, Canada). The edge of
cultured cells was marked by linking cell bodies of furthest, but continually, related
cells from unscratched regions. The edge at 0 and 24h were deﬁned as the injury
line and migration line, respectively. The area between injury and migration lines
was considered as the migration area and was subject to quantiﬁcation.
40 Areas of
migration on images were measured with ImageJ.
Statistical analysis. Data were obtained from at least two independent
experiments, each performed at least in triplicate. Data were expressed as
means±S.E. and analyzed for statistical signiﬁcance by a two-tailed Student’s
t-test. Differences with P-values o0.05 were regarded as statistically signiﬁcant
and are indicated by an asterisk (*) in the ﬁgures.
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